1.26
+0.47(+59.49%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.81 |
| Day High | 1.38 |
| Day Low | 0.78 |
| 52-Week High | 34.92 |
| 52-Week Low | 0.75 |
| Volume | 3.77M |
| Average Volume | 1.39M |
| Market Cap | 4.25M |
| PE | -0.07 |
| EPS | -18.16 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 3.88 |
| Change | 0.46 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $18.36 as of February 14, 2026 at a share price of $1.26. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $453.24 as of February 14, 2026 at a share price of $1.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
GlobeNewswire Inc.
Feb 12, 2026 9:35 PM GMT
This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of t
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
GlobeNewswire Inc.
Feb 12, 2026 1:55 PM GMT
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM
AIM ImmunoTech Announces Commencement of Rights Offering
GlobeNewswire Inc.
Feb 11, 2026 1:30 PM GMT
OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),